[ad_1]
- Next-generation sequencing (NGS) can better understand the genetic mechanisms associated with specific diseases and help promote personalise health care
- Preparing DNA for sequencing library is complicated and prone to human error, which can interfere with accurate sequencing results
- The new AVENIO Edge system is a fully automated solution for sample preparation workflow, from DNA sample input to sequencing-ready library output, and supports more comprehensive testing, providing consistent and high-quality results for future precision medicine
Basel, December 13, 2021-Roche ((6: RO, ROG, OTCQX:RHHBY) Today announced the launch of AVENIO Edge System, which is a core component of Roche’s strategy to advance sequencing technology. Built on top-notch basic functions, it can provide fully automated and integrated sequencing solutions.
AVENIO Edge System is a pre-analysis platform for sequencing library preparation, target enrichment, and quantification steps. It provides integrated end-to-end control and reliable, consistent, high-quality results.
“Roche is committed to developing diagnostic solutions. The goal is to provide the healthcare community with faster and more accurate medical information to predict risks and detect diseases,” said Thomas Schinecker, CEO of Roche Diagnostics. “We are pleased to provide next-generation sequencing laboratories and translational researchers with a new automated AVENIO Edge system designed to significantly reduce human error and help ensure fast, reliable, and accurate results.”
Next-generation sequencing samples are very valuable. Every step of sample preparation may affect the results. The high reproducibility and low error rate of the AVENIO Edge System can support the goal of reducing the number of rejected samples, otherwise these samples may have to be recollected.
In addition to customizable workflow parameters, the new AVENIO Edge system also provides ready-to-use components, making it a scalable, cost-effective solution for sequencing laboratories seeking high performance and agility. When the startup time is set to 20 minutes, this unattended system has reduced the chance of displaying errors by more than 96%, and manual operation time has been reduced by 84%.
The AVENIO Edge System will be available in specific locations around the world, and the timetable varies from country to country.
About the AVENIO Edge system
The AVENIO Edge system is a Class I, in vitro diagnostic (IVD), 510(k) exemption in the United States. According to EU Regulation 2017/746 (IVDR) of the European Parliament and Council of April 5, 2017, it belongs to Class A in the EU…
The full story can be found on Benzinga.com
[ad_2]
Source link
